SAFETY ASSESSMENT OF THE NASVAC, A FORMULATION OF ANTIGENS AS VIRUS-LIKE PARTICLES.

• Dr. Dania Bacardí Fernández

• Spanish / Español

• nasvac
• safety assessment
• virus-like particles

Developing an effective vaccine need a development of a technological framework and compliant with established regulatory and safety requirements. A novel vaccine formulation was designed with mucosal/parenteral simultaneous administration (NASVAC) was obtained at the Center for Genetic Engineering and Biotechnology. The present work describes the preclinical safety strategy based on acute toxicity and repeated doses assays using F1 rabbits and Sprague Dawley rats. The results revealed NASVAC do...